News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Otsuka And Prasco Laboratories Sign A Commercial Supply Agreement For PLETAL Tablets


10/19/2005 5:11:51 PM

Prasco Laboratories, a privately-held pharmaceutical company located in Cincinnati, Ohio, announced today that--under a commercial supply agreement with Otsuka America Pharmaceutical, Inc.--it has initiated shipments of Cilostazol Tablets in the 50 mg and 100 mg strengths. Cilostazol is the authorized generic version of Otsuka's PLETAL(R), which is a PDE-111 inhibitor indicated for the treatment of intermittent claudication (IC). Prasco has received the rights to market 50 mg and 100 mg strength Cilostazol in the United States.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES